France's Cancer Institute faces closure

18 May 2008

France's much-criticized National Cancer Institute (INCa), which was a pet project of the previous President, Jacques Chirac, is among a list of government agencies that are expected to be abolished or merged, as part of a government review. The INCa was described as lacking focus and serious management failings, although claims of criminal mishandling of funds were dismissed by auditors (Marketletter July 10, 2006).

Other affected government agencies in the shake-up are the Biomedicine Agency and both the AFSSA and the AFSSAPS, which regulate food and health care products, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight